Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBerate-CVD phase 3 trial of lerodalcibep in high-risk cardiovascular patients needing additional LDL-C lowering
MOH_2021-10-06_010293Phase 3Recruiting
- Sponsor
- LIB Therapeutics, LLC
- Start
- Jul 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia, atherosclerotic disease and familial hypercholesterolemia (FH) comparing Lerodalcibep with Placebo (2 arms). Started Jul 2021; status: recruiting.
02
Drugs
lerodalcibep
03
Conditions
hypercholesterolemiaatherosclerotic diseasefamilial hypercholesterolemia (FH)
Beyond the preview
Go deeper on MOH_2021-10-06_010293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-10-06_010293.